Cobalt MRI CRT-D (DTPB2Dl, DTPB2D4, DTPB2Ql, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2Dl, DTPA2D4, DTPA2Ql, DTPA2QQ); Crome M
Medtronic Cardiac Rhythm Disease Management · Decision date Oct 5, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-10-05 for PMA supplement P010031/S933 from Medtronic Cardiac Rhythm Disease Management. The supplement is a 30-Day Notice filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the recorded statement of scope is to qualify new manufacturing equipment. The supplement sits under P010031 and covers the Cobalt MRI CRT-D, Cobalt XT MRI CRT-D and Crome M families, with model numbers listed for the Cobalt devices.
The device category is an automatic implantable cardioverter defibrillator with cardiac resynchronization (CRT-D), specialty Cardiovascular, product code NIK. This action concerns manufacturing equipment qualification for the listed CRT-D systems; it is not a new approval of the underlying PMA or a change to the devices' cleared labeling. The source record includes no documents, so the specific equipment, affected manufacturing site and any conditions attached to OK30 are not stated here and remain unknown.
Whether the equipment change alters device performance, sterility or supply is not addressed in the available fields, so no clinical or regulatory conclusion beyond the recorded decision can be drawn.
FDA approval order statement
to qualify new manufacturing equipment
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 5, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010031/S933
- Regulatory pathway
- PMA supplement
- Product code
- NIK
- Decision code
- OK30
- Decision date
- Oct 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D).
- Product code
- NIK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010031 · Original PMA
CONCERTO/INSYNC SENTRY/INSYNC MAXIMO IMPLANTABLE CARDIOVASCULAR DEFIBRILLATORS WITH CARDIAC RESYNCHICNIZATION
P010031/S933 received
Application receipt date recorded by FDA.
P010031/S932 · Related supplement
Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D
P010031/S933 · FDA decision
30-Day Notice
P010031/S934 · Related supplement
Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D
P010031/S931 · Related supplement
Cobalt MRI CRT-D (DTPB2D1, DTPB2D4, DTPB2Q1, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2D1, DTPA2D4, DTPA2Q1, DTPA2QQ); Crome M
Timeline entries are records held by MedtechLedger for P010031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Cardiac Rhythm Disease Management | PMA approval | Jun 26, 2002 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Sep 25, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Cardiac Rhythm Disease Management
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P010031/S933
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


